Literature DB >> 22459564

Nigro-striatal involvement in primary progressive freezing gait: insights into a heterogeneous pathogenesis.

Alfonso Fasano1, Sergio Baldari, Daniela Di Giuda, Rosario Paratore, Carla Piano, Anna Rita Bentivoglio, Paolo Girlanda, Francesca Morgante.   

Abstract

Primary progressive freezing gait (PPFG) is a clinical syndrome underlain by diverse neurodegenerative diseases and characterized by early occurrence of gait freezing. Either degeneration or integrity of the nigrostriatal terminals have been found by SPECT and PET studies. In this retrospective study, we evaluated (123)I-FP-CIT SPECT findings in a consecutive series of 13 PPFG patients with detailed clinical evaluation over time (mean follow-up duration: 3.1 ± 1.2 years). In all patients, (123)I-FP-CIT SPECT has been performed at the time of first clinical evaluation (1.7 ± 1.4 years after disease onset) and was compared with data from 23 age- and sex-matched healthy subjects. PPFG patients were categorized as having abnormal (n = 8) or normal (n = 5) SPECT. At disease onset, PPFG with abnormal SPECT had more frequent hypophonia, higher UPDRS-III scores and partial levodopa responsiveness. By contrast, PPFG with normal SPECT had more frequent bilateral plantar responses and no response to levodopa. At latest follow-up, initial diagnosis in the abnormal SPECT group was revised (n = 5) to progressive supranuclear palsy (n = 4) and pure akinesia with gait freezing (n = 1). Among the five patients with normal SPECT, follow-up evaluation disclosed corticobasal syndrome (n = 2) and primary lateral sclerosis (n = 1). Dopamine transporter imaging can capture the clinical heterogeneity of PPFG and might have a value to predict possible disease progression.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22459564     DOI: 10.1016/j.parkreldis.2012.03.002

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  7 in total

1.  Primary progressive freezing gait with impressive response to laser light visual cueing: a video case report.

Authors:  Moisés León Ruiz; Miguel Á García-Soldevilla; Esteban García-Albea Ristol
Journal:  J Neurol       Date:  2018-07-13       Impact factor: 4.849

Review 2.  Early perfusion and dopamine transporter imaging using 18F-FP-CIT PET/CT in patients with parkinsonism.

Authors:  Chae-Moon Hong; Ho-Sung Ryu; Byeong-Cheol Ahn
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-12-20

3.  Cardiac sympathetic denervation in Parkinson's disease patients with SWEDDs.

Authors:  Wooyoung Jang; Joong-Seok Kim; Jin Whan Cho; Young Hwan Kim; Ji Young Kim; Yun Young Choi; Hee-Tae Kim
Journal:  Neurol Sci       Date:  2012-11-24       Impact factor: 3.307

Review 4.  Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Authors:  Jennifer L Whitwell; Günter U Höglinger; Angelo Antonini; Yvette Bordelon; Adam L Boxer; Carlo Colosimo; Thilo van Eimeren; Lawrence I Golbe; Jan Kassubek; Carolin Kurz; Irene Litvan; Alexander Pantelyat; Gil Rabinovici; Gesine Respondek; Axel Rominger; James B Rowe; Maria Stamelou; Keith A Josephs
Journal:  Mov Disord       Date:  2017-05-13       Impact factor: 10.338

5.  Degeneration of corticofugal fibers in a patient with primary progressive freezing gait: A case report.

Authors:  Jeong Pyo Seo; Min Cheol Chang
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

6.  Cortical Activation During Levitation and Tentacular Movements of Corticobasal Syndrome.

Authors:  Marco Onofrj; Laura Bonanni; Stefano Delli Pizzi; Massimo Caulo; Valeria Onofrj; Astrid Thomas; Armando Tartaro; Raffaella Franciotti
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

Review 7.  Neuroimaging of Freezing of Gait.

Authors:  Alfonso Fasano; Talia Herman; Alessandro Tessitore; Antonio P Strafella; Nicolaas I Bohnen
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.